Biogen Idec Inc
BIIB:NASDAQ
| 最新 | 变化/%变化 | 股息收益率 | 交易量 | Avg Volume (10 day) |
| 175.52 | 0.00 0.00% | 0.00% | 0 | 1.3M |
市场数据至少延迟20分钟
Biogen Idec Inc的最新新闻标题
Next Support Level for Biogen Idec (BIIB) is $174.49
Shares of Biogen Idec (NASDAQ:BIIB) have bearishly opened below the pivot of $176.91 today and have reached the first support level of $175.63. Investors may be interested in a cross of the next downside pivot targets of $174.49 and $172.07.
ADDING MULTIMEDIA New TYSABRI Data Reaffirm Substantial Efficacy in Treatment of People with MS and Demonstrate Stability of Anti-JCV Antibody Status
Biogen Idec (NASDAQ: BIIB) and Elan
Corporation, plc (NYSE: ELN) announced results from several studies of
TYSABRI(R) (natalizumab) that demonstrate its efficacy
compared to other multiple sclerosis (MS) treatments, provide additional
data supporting anti-JC virus (JCV) antibody status stability, and
suggest better outcomes when progressive multifocal leukoencephalopathy
(PML) is detected early. These data will be presented at the 65th Annual
Meeting of the American Academy of Neurology (AAN) in San Diego.
New TYSABRI Data Reaffirm Substantial Efficacy in Treatment of People with MS and Demonstrate Stability of Anti-JCV Antibody Status
查看更多最新标题Biogen Idec (NASDAQ: BIIB) and Elan
Corporation, plc (NYSE: ELN) announced results from several studies of
TYSABRI(R) (natalizumab) that demonstrate its efficacy
compared to other multiple sclerosis (MS) treatments, provide additional
data supporting anti-JC virus (JCV) antibody status stability, and
suggest better outcomes when progressive multifocal leukoencephalopathy
(PML) is detected early. These data will be presented at the 65th Annual
Meeting of the American Academy of Neurology (AAN) in San Diego.
公司背景
Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company's products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland.
买方价/量 -- / -- | 卖方价/量 -- / -- |
开盘价格 0.00 | 前收盘价格 175.52 |
当天最高 0.00 | 当天最低 0.00 |
52周高/日期 178.18 / 3/15/2013 | 52周低/日期 118.52 / 3/21/2012 |
% off 52wk High -1.49% | % off 52wk Low 48.09% |
贝他(5年) 0.9 | 市值 41.5B |
流通股数 236.3M | 波动平均(Volatility Avg) 19.81 |
每股收益(EPS)(TTM) 5.76 | 市盈率(P/E) 30.5x |
股息宣布日 -- | 股息收益率 0.00% |
除息日 -- | 登记日 -- |
支付数额 0.00 - -- | 支付日期 -- |
上次交易3/18/2013 4:00 PM ET | |
BIIB Biogen Idec Inc 对比同行
| 同行 | |
|---|---|
BIIB Biogen Idec Inc | 19.92% |
Pfizer Inc. | 11.81% |
Johnson & Johnson | 12.43% |
Abbott Laboratories | 6.76% |
Amgen, Inc. | 4.86% |
BIIB Biogen Idec Inc | 0.00% |
Pfizer Inc. | 3.42% |
Johnson & Johnson | 3.10% |
Abbott Laboratories | 1.67% |
Amgen, Inc. | 2.08% |
BIIB Biogen Idec Inc | 0.00% |
Pfizer Inc. | 0.00% |
Johnson & Johnson | 0.00% |
Abbott Laboratories | 0.00% |
Amgen, Inc. | 0.00% |